Abstract:Pancreatic ductal adenocarcinoma (PDAC) is the most malignant cancer type with 5-year survival rate less than 8%, largely due to inefficient diagnosis and tenacious drug resistance. The development of dense stroma is its prominent feature, accounting for its aggressive biology and pivotal for its progression and drug resistance. The stroma not only just acts as a mechanical barrier to impede drug access, but also provides a unique growth-permissive environment to promote tumor progression and metastasis and to circumvent immune surveillance. The pancreatic stellate cell (PSC) is a key player in the formation and turnover of pancreatic tumor stroma, and the reciprocal interplay between PSCs and pancreatic cancer cells (PCCs) not only enhances tumor progression and metastasis but also sustains their own activation, facilitating a vicious circle to exacerbate tumorigenesis and drug resistance. Moreover, PSC activation occurs very early during PDAC tumorigenesis, and activated PSCs comprise a significant fraction of the tumor mass, providing a rich source of readily detectable factors. Therefore, a better understanding of the communication between PSCs and PCCs should shed light on the vulnerability amenable for PDAC therapy and diagnosis. To comprehensively investigate the process, we performed systematic proteomic analysis of the dynamic changes in both the composition and intracellular signal transduction stimulation of the secretomes of pancreatic stellate cells (PSCs) and pancreatic cancer cells (PCCs). Among many intriguing findings, we revealed leukemia inhibitory factor (LIF) as a key paracrine factor, mainly secreted by activated stromal PSCs, to mediate the intercellular communication. Both pharmacologic LIF blockade and genetic Lifr deletion significantly slow tumor progression and augment chemotherapy efficacy to prolong survival of PDAC mouse models, mainly by modulating cancer cell differentiation and EMT status. Moreover, we found that, consistently in both mouse models and human PDAC, aberrant production of LIF in the pancreas is unique to pathologic conditions and correlates with PDAC pathogenesis, and changes in circulating LIF level correlate well with tumor response to therapy. As such, this study established LIF as an attractive therapeutic target and biomarker. Recently, we expanded our analysis by proteomic profiling on human pancreatic normal vs. tumor tissues focused mainly on the secreted and cell-membrane proteins by specific pre-enrichment to catalog the active ligand-receptor pairs and corresponding communications underlying to further broaden our understanding of paracrine interactions between PSCs and PCCs and to explore its potential translational application. Citation Format: Yu Shi, Ruijun Tian, Tony Hunter. LIF-mediated crosstalk between pancreatic stellate and cancer cells and its translational application [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2019 Sept 6-9; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2019;79(24 Suppl):Abstract nr A49.

An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy

Antagonist anti-LIF antibody derived from naive human scFv phage library inhibited tumor growth in mice

Abstract A49: LIF-mediated Crosstalk Between Pancreatic Stellate and Cancer Cells and Its Translational Application

Abstract B095: Leukemia inhibitory factor fosters tumor growth in KRAS-driven pancreatic ductal adenocarcinoma

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring

Leukemia Inhibitory Factor Receptor Negatively Regulates the Metastasis of Pancreatic Cancer Cells in Vitro and in Vivo.

570 Blockade of the Inhibitory Collagen Receptor LAIR-1, PD-L1, and TGF-β Promotes Anti-Tumor Activity Through T Cell Activation and Myeloid Cell Polarization

Abstract 7465: Leukemia inhibitory factor creates an immune suppressive tumor microenvironment and fosters tumor growth in KRAS-driven pancreatic ductal adenocarcinoma

Author Correction: Targeting LIF-mediated Paracrine Interaction for Pancreatic Cancer Therapy and Monitoring

Abstract 1062: Antiproliferative activity of EC359, an inhibitor of leukemia inhibitory factor receptor (LIF-R), singly and in combination with chemotherapy drugs against pancreatic cancer cell lines

A Novel Small Molecular Prostaglandin Receptor EP4 Antagonist, L001, Suppresses Pancreatic Cancer Metastasis

Transient and Local Expression of Chemokine and Immune Checkpoint Traps to Treat Pancreatic Cancer.

LIF drives neural remodeling in pancreatic cancer and offers a new candidate biomarker.

Abstract 7470: Leukemia inhibitory factor promotes tumor progression in KRAS-driven lung cancer

Abstract 5975: Characterization and pharmacokinetics of ligand traps targeting the human epidermal growth factor receptor (HER) family

A New Fusion Peptide Targeting Pancreatic Cancer and Inhibiting Tumor Growth.

Abstract 1414: HBM9014, a first-in-class fully human anti-LIFR antibody with excellent preclinical efficacy and safety profile

The emerging role of leukemia inhibitory factor in cancer and therapy

Roles of leukemia inhibitory factor receptor in cancer

Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment

Apolipoprotein A-I mimetic peptide 4F suppresses tumor-associated macrophages and pancreatic cancer progression